Idera Pharmaceuticals

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare autoimmune diseases. The Company's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like receptors (TLRs). In addition to its TLR programs, it is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
1989
Size (employees)
62 (est)
Idera Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, US

Key People at Idera Pharmaceuticals

Sudhir Agrawal

Sudhir Agrawal

Chief Executive Officer and President, Board of Directors
Louis J. Arcudi

Louis J. Arcudi

Senior Vice President of Operations, Chief Financial Officer, Treasurer, and Secretary
Robert D. Arbeit

Robert D. Arbeit

Vice President, Clinical Development
Timothy M. Sullivan

Timothy M. Sullivan

Vice President, Development Programs and Alliance Management

Idera Pharmaceuticals Office Locations

Idera Pharmaceuticals has offices in Cambridge and Exton
Cambridge, US (HQ)
167 Sidney Street
Exton, US
505 Eagleview Blvd, Suite 212

Idera Pharmaceuticals Data and Metrics

Idera Pharmaceuticals Financial Metrics

Idera Pharmaceuticals's revenue was reported to be $249 k in FY, 2015
USD

Net income (Q1, 2017)

(15.1 m)

EBIT (Q1, 2017)

(15.2 m)

Market capitalization (22-Aug-2017)

263 m

Cash (31-Dec-2016)

80.7 m

EV

182.6 m
Idera Pharmaceuticals's current market capitalization is $263 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

47 k73 k249 k

Revenue growth, %

55%241%

Net Income

(18.2 m)(38.6 m)(48.6 m)(38.4 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

9 m7.5 m9.3 m10.1 m9.4 m11.5 m

General and administrative expense

3.8 m4 m3.9 m3.8 m3.9 m4.1 m

Operating expense total

12.8 m11.5 m13.2 m13.9 m13.3 m15.6 m

EBIT

(12.8 m)(11.5 m)(12.9 m)(13.6 m)(13 m)(15.2 m)

Interest expense

27 k23 k21 k19 k16 k

Interest income

120 k110 k90 k153 k

Net Income

(12.7 m)(11.4 m)(12.8 m)(13.5 m)(12.9 m)(15.1 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

26.3 m20 m26.6 m80.7 m

Inventories

874 k1.2 m3.1 m2 m

Current Assets

30.3 m42.4 m63.2 m111 m

PP&E

90 k1.3 m1.7 m1.9 m

Total Assets

36.9 m51.4 m92.3 m113.2 m

Accounts Payable

904 k2.5 m1.2 m556 k

Total Debt

292 k

Current Liabilities

4.4 m7 m6.8 m9.4 m

Total Liabilities

9.9 m

Additional Paid-in Capital

434.3 m494.9 m583.7 m641.7 m

Retained Earnings

(412.9 m)(451.5 m)(500.1 m)(538.5 m)

Total Equity

32.5 m43.4 m83.6 m103.3 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.1 x1.2 x1.1 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18.2 m)(38.6 m)(48.6 m)(38.4 m)

Depreciation and Amortization

137 k206 k488 k656 k

Inventories

(676 k)(329 k)(1.9 m)1.1 m

Cash From Operating Activities

(17.1 m)(31.3 m)(43 m)(28.2 m)

Purchases of PP&E

(9 k)(1.1 m)(727 k)(408 k)

Cash From Investing Activities

(9.3 m)(20.6 m)(33.4 m)31.4 m

Short-term Borrowings

(4 k)(5 k)(10 k)(7 k)

Dividends Paid

(1.1 m)(798 k)(798 k)(798 k)

Cash From Financing Activities

42.7 m45.6 m83 m50.9 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(12.7 m)(11.4 m)(12.8 m)(13.5 m)(12.9 m)(15.1 m)

Accounts Payable

2.8 m881 k958 k629 k344 k1.4 m
Y, 2017

EV/EBIT

-12 x

Idera Pharmaceuticals Market Value History

Traffic Overview of Idera Pharmaceuticals

Idera Pharmaceuticals Company Life and Culture

You may also be interested in